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Untapped	resources	
for	medical	research	
A	 therapeutic	 solution	 to	 the	 current	 corona-
virus	 (COVID-19)	pandemic	 is	 urgently	needed,	
but	 new	 drug	 discovery	 and	 development	 is	 a	
lengthy	 process.	 Pharmaceuticals	 derived	 from	
plants	 and	 fungi	 remain	 important	 in	 our	 ar-
mory	 against	 numerous	 diseases	 (1,	 2),	 yet	
much	 of	 plant	 and	 fungal	 biodiversity	 remains	
unexplored	 for	 drug	 discovery	 (3).	 Of	 about	
390,000	known	plant	 species,	7%	have	medici-
nal	 uses	 (4),	 and	 the	 wider	 potential	 of	 the	
world’s	 flora	 to	 yield	 new	medicines	 has	 been	
discussed	by	conservation	biologists	for	decades	
(5).	 We	 urgently	 need	 a	 comprehensive	 scien-
tific	 study	of	biodiversity	 to	 inspire,	 accelerate,	
and	innovate	medicinal	discovery.		
Acquiring	usable	plant	and	fungal	material	is	
resource-consuming,	but	a	partial	solution	lies	in	
specimens	 already	 housed	 in	 herbaria,	 botanic	
gardens	(6),	and	fungal	biological	resource	cen-
ters.	Herbaria	host	about	380	million	specimens	
from	 all	 described	 plant	 species,	 and	 botanic	
gardens	maintain	about	one-third	of	all	known	
land	 plant	 species	 (7).	 Fungal	 collections	 cur-
rently	host	about	860,000	strains	worldwide	(8).	
These	 collections	 are	 invaluable	 resources	 rep-
resenting	unparalleled	chemical	diversity.		
Evolutionary	 relationships	 inferred	 from	
DNA	could	be	used	to	guide	selection	of	species	
with	medicinal	 potential.	 Just	 a	 few	milligrams	
from	 specimens	 enable	 comprehensive	 chemi-
cal	 profiling,	 uncovering	 new	 chemical	 entities	
that	share	chemical	or	physical	characteristics	to	
drug	molecules,	potentially	with	novel	modes	of	
action	(1,	2).	Artificial	intelligence	and	emerging	
technologies	 could	 reveal	 compounds	 with	
mechanistic	effects	relevant	to	diseases	threat-
ening	humanity	(2,	9).	Furthermore,	collections	
are	increasingly	used	to	generate	genomic	data,	
which	 could	 be	 used	 to	 identify	 members	 of	
gene	families	known	to	be	 involved	 in	the	syn-
thesis	of	useful	compounds	(10).		
Investing	in	a	new	era	of	large-scale	explora-
tion	 of	 therapeutic	 candidates	 from	 nature	
could	 help	 humanity	 prepare	 for	 future	 health	
challenges.	 Scientists,	 stakeholders	 and	 gov-
ernments	must	establish	functional	and	equita-
ble	 agreements	 to	 ensure	 that	 this	work	 com-
plies	 with	 the	 Nagoya	 Protocol,	 Access	 and	
Benefit	Sharing	legislation	and	reflects	the	value	
and	 origins	 of	 specimens	 collected	 during	 the	
colonial	 era	 (11).	 It	 is	 also	 critical	 that	benefits	
revert	 to	 the	 nations	 and	 ethnic	 groups	 from	
where	these	resources	derive	(12).		
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